Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status - United States, January 22-October 3, 2020
Overview
Authors
Affiliations
Studies suggest that pregnant women might be at increased risk for severe illness associated with coronavirus disease 2019 (COVID-19) (1,2). This report provides updated information about symptomatic women of reproductive age (15-44 years) with laboratory-confirmed infection with SARS-CoV-2, the virus that causes COVID-19. During January 22-October 3, CDC received reports through national COVID-19 case surveillance or through the National Notifiable Diseases Surveillance System (NNDSS) of 1,300,938 women aged 15-44 years with laboratory results indicative of acute infection with SARS-CoV-2. Data on pregnancy status were available for 461,825 (35.5%) women with laboratory-confirmed infection, 409,462 (88.7%) of whom were symptomatic. Among symptomatic women, 23,434 (5.7%) were reported to be pregnant. After adjusting for age, race/ethnicity, and underlying medical conditions, pregnant women were significantly more likely than were nonpregnant women to be admitted to an intensive care unit (ICU) (10.5 versus 3.9 per 1,000 cases; adjusted risk ratio [aRR] = 3.0; 95% confidence interval [CI] = 2.6-3.4), receive invasive ventilation (2.9 versus 1.1 per 1,000 cases; aRR = 2.9; 95% CI = 2.2-3.8), receive extracorporeal membrane oxygenation (ECMO) (0.7 versus 0.3 per 1,000 cases; aRR = 2.4; 95% CI = 1.5-4.0), and die (1.5 versus 1.2 per 1,000 cases; aRR = 1.7; 95% CI = 1.2-2.4). Stratifying these analyses by age and race/ethnicity highlighted disparities in risk by subgroup. Although the absolute risks for severe outcomes for women were low, pregnant women were at increased risk for severe COVID-19-associated illness. To reduce the risk for severe illness and death from COVID-19, pregnant women should be counseled about the importance of seeking prompt medical care if they have symptoms and measures to prevent SARS-CoV-2 infection should be strongly emphasized for pregnant women and their families during all medical encounters, including prenatal care visits. Understanding COVID-19-associated risks among pregnant women is important for prevention counseling and clinical care and treatment.
Infection with SARS-CoV-2 during pregnancy and risk of stillbirth: a Scandinavian registry study.
Magnus M, Ortqvist A, Urhoj S, Aabakke A, Mortensen L, Gjessing H BMJ Public Health. 2025; 1(1):e000314.
PMID: 40017848 PMC: 11812723. DOI: 10.1136/bmjph-2023-000314.
Brendolin M, Wakimoto M, Oliveira R, Mageste L, Nielsen-Saines K, Brasil P Viruses. 2025; 17(2).
PMID: 40006963 PMC: 11860397. DOI: 10.3390/v17020207.
Pregnancy and COVID-19: Comparing ICU Outcomes for Pregnant and Nonpregnant Women.
Lipinska-Gediga M, Gozdzik W, Smiechowicz J, Adamik B Viruses. 2025; 17(1).
PMID: 39861839 PMC: 11768449. DOI: 10.3390/v17010051.
Qin C, Ding Y, Liu M, Liu J Hum Vaccin Immunother. 2025; 21(1):2450131.
PMID: 39797690 PMC: 11730418. DOI: 10.1080/21645515.2025.2450131.
PostCOVID-19 Impact on Perinatal Outcomes.
Kurmanova G, Ayazbekov A, Kurmanova A, Rakhimbayeva M, Trimova G, Kulembayeva A Diagnostics (Basel). 2025; 15(1.
PMID: 39795585 PMC: 11719491. DOI: 10.3390/diagnostics15010057.